This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

A targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions and confirm whether cancer remains after therapy. The phase 2 clinical trial was led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Multiple myeloma is a disease that can remain hidden in plain sight. This blood cancer grows in the bone marrow but spreads to many places in the body. Doctors can use advanced imaging and newer blood tests to look for disease, but these tests do not always tell the full story, which can affect everything from diagnosis to treatment decisions.

Now, Sylvester researchers have shown that a targeted imaging approach can detect active myeloma that standard tests miss.

The study, published in Radiology, used immunoPET, which uses labeled antibodies that find and attach directly to myeloma cells.

"If we are going to cure multiple myeloma, we need two things. One, we need really effective medicines. Second, we need to be able to make sure there is no disease left behind after these treatments," said C. , chief of the Myeloma Division, director of Sylvester Myeloma Institute and senior author of the study.

Source link